Logo

Novavax Reports Results of ResVax in P-III PREPARE Trial for Prevention of RSV Disease in Infants via Maternal Immunization

Share this

Novavax Reports Results of ResVax in P-III PREPARE Trial for Prevention of RSV Disease in Infants via Maternal Immunization

Shots:

  • The P-III PREPARE study involves assessing ResVax vs PBO in 4-636 pregnant women to prevent the risk of RSV Disease in infants
  • PREPARE study results: didn’t met 1EPs @prevention of medically significant RSV LRTI; 39% against medically significant RSV LRTI; 44% against RSV LRTI hospitalizations; 48% against RSV LRTI with severe hypoxemia; reduction in LRTI  hospitalizations & hypoxemia (25% & 39%); vaccine efficacy against RSV LRTI hospitalization & hypoxemia@< 33wks. pregnancy (53%-70% vs 26%-44%)
  • ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine used in combination with aluminum phosphate for prevention of severe LRTI in infants >1yrs.

Ref: Novavax | Image: Getty images

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions